News
01.07.20

Ocular Science Taps Longtime Ophthalmology Medical Device Pro to Lead U.S. Sales

Greg Anderson, new vice president of sales, brings more than 25 years of ophthalmic medical sales and marketing experience to SoCal biotech specializing in cost-effective, and easy-to-use ophthalmic formulations. 
 
MANHATTAN BEACH, Calif. (Jan. 7, 2020)
– Ocular Science®, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has named Greg Anderson as its vice president of sales.  Anderson, most recently the Vice President of Market Development at Restoration Robotics, possesses more than 25 years of ophthalmic medical device industry experience. He will be overseeing sales for two Ocular Science affiliates: OSRXTM, a 503A compounding pharmacy; and Regenerative ScienceTM, which produces biologics to manage dry eye disease.

“I’ve known Greg personally and professionally for more than a decade, and he’s one of the most hard-working, dedicated medical sales leaders in the ophthalmic industry,” says Ocular Science CEO Anthony Sampietro, who co-founded the Southern California-based biotech company in 2015.  “Ocular Science experienced a 90 percent compounded annual growth rate last year and we’re expanding at a rapid pace, so Greg’s leadership savvy, longstanding relationships, insights and unique experience with disruptive medical technologies will be invaluable for our short- and long-term corporate efforts.”

OSRX, located in Missoula, Mont., compounds 13 customized formulations – branded OMNITM – that combine multiple medications into a single dose for post-op cataract and LASIK treatment, glaucoma management and myopia control. Additionally, OSRX is currently developing a much-anticipated formulation for the treatment of presbyopia called EyeFocusTM. The prescription eye drop is slated for launch in early 2020. 

Regenerative Science, based in Manhattan Beach, Calif., is in the process of commercializing three amnion-derived eye drops – Genesis 2.0TM, ACETM and RenaissanceTM – each possessing a proprietary combination of cytokines, growth factors, proteins and molecules aimed at relieving dry eye symptoms for the more than five million sufferers in the U.S.

“I’ve closely followed Ocular Science for the last four years and I look forward to leveraging my sales and leadership experience in ophthalmology to boost their exceptional year-over-year growth,” says Anderson. “With the continual reimbursement pressure on physicians and accelerating prescription medication expenses on patients, Ocular Science offers logical economic and pragmatic solutions to physicians, their staff and their patients.”

Germane to Ocular Science, Anderson has worked as a senior-level leader for several early-stage medical device, venture-funded start-ups, building and re-building numerous sales teams and working on several new product launches. Prior to Restoration Robotics, Anderson was Director of U.S. Sales at Fortune 500 company Abbott Vision, Vice President of Sales at OptiMedica, IntraLase and WaveLight, and spent 14 years at Coherent Medical, now Lumenis. 

“Ocular Science provides uncompromising patient care, affordable medications and exceptional customer services that make the entire sales and onboarding process seamless for physicians and their front office staff,” says Anderson. “I’m thrilled to be part of the team and I look forward to contributing to the company’s growth and unique value proposition.”
For more information on Ocular Science and its affiliates, visit ocularscience.com

Media Contact: Eric Garner, Ocular Science VP of Marketing – (541) 413-2880; ehgarner@ocularscience.com